Mesa Laboratories, Inc. announced that it has entered into separate, privately negotiated purchase agreements with a limited number of holders of its outstanding 2025 Notes at the gross proceeds of $71,250,000 on April 5, 2024. The principal amount of the transaction is $75,000,000. The notes bear 1.375% Convertible Notes due 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113.4 USD | +2.90% | +11.37% | +8.21% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.21% | 594M | |
-3.77% | 184B | |
-1.77% | 107B | |
-1.43% | 67.52B | |
+2.06% | 50.06B | |
+9.43% | 45.67B | |
+3.40% | 41B | |
+3.04% | 26.73B | |
+4.64% | 26.47B | |
+15.23% | 25.05B |
- Stock Market
- Equities
- MLAB Stock
- News Mesa Laboratories, Inc.
- Mesa Laboratories, Inc. announced that it expects to receive $71.25 million in funding